HBK Investments’s Starling Oncology STLN Stock Holding History

HBK Investments’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-450,000	Closed	-$4.47M	–	853
2021 Q3	$4.47M	Hold	450,000	–	–	0.02%	280
2021 Q2	$4.48M	Hold	450,000	–	–	0.02%	326
2021 Q1	$4.48M	Sell	450,000 -9,558	-2%	-$102K	0.02%	290
2020 Q4	$4.96M	Sell	459,558 -40,442	-8%	-$416K	0.03%	282
2020 Q3	$5.18M	Hold	500,000	–	–	0.04%	216
2020 Q2	$5.03M	Buy	+500,000	New	+$4.97M	0.07%	191

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

HBK Investments's STLN Position: Q4 2021 in Review

HBK Investments sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 450,000 shares — an estimated $4.47M sold.

HBK Investments first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $5.18M in Q3 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

HBK Investments reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
HBK Investments sold 450,000 Starling Oncology shares in Q4 2021, an estimated $4.47M.
HBK Investments first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
HBK Investments's Starling Oncology position peaked at $5.18M in Q3 2020.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on HBK Investments's 13F filing for Q4 2021, filed 14 Feb 2022.